menu
    • menu

    Find Cobimetinib manufacturers, exporters & distributors on PharmaCompass

    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    0

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    0

    NDC API

    NDC API

    0

    VMF

    NDC API

    0

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    10

    FDF Dossiers

    FDF Dossiers

    1

    FDA Orange Book

    FDA (Orange Book)

    5

    Europe

    Europe

    1

    Canada

    Canada

    2

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    75DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    97RELATED EXCIPIENT COMPANIES

    146EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    13

    US Patents

    4

    US Exclusivities

    2

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    6,345,616

    Annual Reports

    NA

    Regulatory FDF Prices

    Listed Dossiers
    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    1

    API

    1

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    16

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 934660-93-2, Gdc-0973, Xl518, Xl-518, Gdc 0973, Rg7420
    Molecular Formula
    C21H21F3IN3O2
    Molecular Weight
    531.3  g/mol
    InChI Key
    BSMCAPRUBJMWDF-KRWDZBQOSA-N
    FDA UNII
    ER29L26N1X
    Cobimetinib
    Cobimetinib is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.
    Cobimetinib is a Kinase Inhibitor. The mechanism of action of cobimetinib is as a Kinase Inhibitor.
    1 2D Structure

    Cobimetinib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl]methanone
    2.1.2 InChI
    InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1
    2.1.3 InChI Key
    BSMCAPRUBJMWDF-KRWDZBQOSA-N
    2.1.4 Canonical SMILES
    C1CCNC(C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
    2.1.5 Isomeric SMILES
    C1CCN[C@@H](C1)C2(CN(C2)C(=O)C3=C(C(=C(C=C3)F)F)NC4=C(C=C(C=C4)I)F)O
    2.2 Other Identifiers
    2.2.1 UNII
    ER29L26N1X
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone

    2. Cotellic

    3. Gdc-0973

    4. Xl518

    2.3.2 Depositor-Supplied Synonyms

    1. 934660-93-2

    2. Gdc-0973

    3. Xl518

    4. Xl-518

    5. Gdc 0973

    6. Rg7420

    7. Xl 518

    8. Rg 7420

    9. Er29l26n1x

    10. Chembl2146883

    11. [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2s)-piperidin-2-yl]azetidin-1-yl]methanone

    12. Cobimetinib (gdc-0973, Rg7420)

    13. (s)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone

    14. [3,4-bis(fluoranyl)-2-[(2-fluoranyl-4-iodanyl-phenyl)amino]phenyl]-[3-oxidanyl-3-[(2s)-piperidin-2-yl]azetidin-1-yl]methanone

    15. Methanone, (3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-((2s)-2-piperidinyl)-1-azetidinyl)-

    16. [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((s)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone

    17. Eui

    18. Cobimetinib Butyrate

    19. Cobimetinib [usan]

    20. 934660-94-3

    21. Cobimetinib [usan:inn]

    22. Cometinib

    23. Unii-er29l26n1x

    24. C21h21f3in3o2

    25. Cobimetinib [mi]

    26. Cobimetinib [inn]

    27. Cobimetinib (usan/inn)

    28. Cobimetinib [who-dd]

    29. Schembl189565

    30. Gtpl7626

    31. Xl518;rg7420;cobimetinib

    32. Chebi:90851

    33. Dtxsid60239435

    34. Ex-a673

    35. Gdc0973

    36. Gdc0973; Xl518; Cobimetinib

    37. Bdbm50391802

    38. Mfcd22124461

    39. Nsc768068

    40. Nsc781257

    41. Nsc800075

    42. S8041

    43. Zinc60325170

    44. Bcp9000716

    45. Ccg-264727

    46. Cs-0521

    47. Db05239

    48. Nsc-768068

    49. Nsc-781257

    50. Nsc-800075

    51. Vs-0129

    52. Xl518 (gdc-0973)

    53. Ncgc00346455-03

    54. Ncgc00346455-05

    55. (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone

    56. (s)-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)(3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl)methanone

    57. Hy-13064

    58. Ro-5514041

    59. D10405

    60. J-525162

    61. Q15708292

    62. ((3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl)(3-hydroxy-3-((2s)-piperidin-2-yl)azetidin-1-yl)methanone

    63. (3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)(3-hydroxy-3-((s)-piperidin-2-yl)cyclobutyl)methanone

    64. [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]-[3-hydroxy-3-[(2s)-piperidin-2-yl]azetidin

    65. [3,4-difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2s)-piperidin-2-yl]azetidin-1-yl}methanone

    66. [3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl]-[3-hydroxy-3-[(2s)-piperidin-2-yl]azetidin-1-yl]methanone

    67. {3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}{3-hydroxy-3-[(2s)-piperidin-2-yl]azetidin-1-yl}methanone

    2.4 Create Date
    2007-07-23
    3 Chemical and Physical Properties
    Molecular Weight 531.3 g/mol
    Molecular Formula C21H21F3IN3O2
    XLogP33.9
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count4
    Exact Mass531.06306 g/mol
    Monoisotopic Mass531.06306 g/mol
    Topological Polar Surface Area64.6 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity624
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.

    FDA Label

    Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

    Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue) with Ras, Raf or MEK pathway activation

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Cobimetinib is a reversible inhibitor of mitogen-activated protein kinase 1 (MAPK)/extracellular signal regulated kinase 1 (MEK1) and MEK2. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a BRAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signalling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases. Cobimetinib is used in combination with vemurafenib because the clinical benefit of a BRAF inhibitor is limited by intrinsic and acquired resistance. Reactivation of the MAPK pathway is a major contributor to treatment failure in BRAF-mutant melanomas, approximately ~80% of melanoma tumors becomes BRAF-inhibitor resistant due to reactivation of MAPK signalling. BRAF-inhibitor resistant tumor cells are sensitive to MEK inhibition, therefore cobimetinib and vemurafenib will result in dual inhibition of BRAF and its downstream target, MEK.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    COBIMETINIB
    5.2.2 FDA UNII
    ER29L26N1X
    5.2.3 Pharmacological Classes
    Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
    5.3 ATC Code

    L01XE38

    L01XE38

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EE - Mitogen-activated protein kinase (mek) inhibitors

    L01EE02 - Cobimetinib

    5.4 Absorption, Distribution and Excretion

    Absorption

    The bioavailability of cobimetinib is 46%, the AUC and Cmax is unaffected by food.

    Route of Elimination

    76% of the dose was recovered in feces with 6.6% as unchanged drug. 17.8% of the dose was recovered in urine with 1.6% as unchanged drug.

    Volume of Distribution

    806L in cancer patients based on a population PK analysis.

    Clearance

    13.9L/h

    5.5 Metabolism/Metabolites

    Cobimetinib is mainly metabolized via CYP3A oxidation and UGT2B7 glucuronidation with no major metabolites formed.

    5.6 Biological Half-Life

    Average half life was 44 hours.

    5.7 Mechanism of Action

    MEK inhibitor Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Cobimetinib and vemurafenib target two different kinases in the RAS/RAF/MEK/ERK pathway.

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

    Details:

    Vemurafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neoplasms.


    Lead Product(s): Vemurafenib,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

    Sponsor: University of Manchester | University of Birmingham | Royal Marsden NHS Foundation Trust | F. Hoffmann-La Roche

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 14, 2023

    blank

    01

    Cancer Research UK

    Country
    arrow
    World Dairy Expo
    Not Confirmed

    Cancer Research UK

    Country
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vemurafenib,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II/ Phase III

    Partner/Sponsor/Collaborator : University of Manchester | University of Birmingham | Royal Marsden NHS Foundation Trust | F. Hoffmann-La Roche

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients Wi...

    Details : Vemurafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    March 14, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

    Details:

    T3011 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.


    Lead Product(s): T3011,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Microorganism

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 06, 2023

    blank

    02

    ImmVira

    China
    arrow
    World Dairy Expo
    Not Confirmed

    ImmVira

    China
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : T3011,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma

    Details : T3011 is a Microorganism drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

    Product Name : Undisclosed

    Product Type : Microorganism

    Upfront Cash : Inapplicable

    March 06, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant Cancers

    Details:

    InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and China.


    Lead Product(s): Ifebemtinib,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Hyfinity Investments

    Deal Size: $15.0 million Upfront Cash: Undisclosed

    Deal Type: Series B Financing May 09, 2022

    blank

    03

    InxMed

    China
    arrow
    World Dairy Expo
    Not Confirmed

    InxMed

    China
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ifebemtinib,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Hyfinity Investments

    Deal Size : $15.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    InxMed Raised $15 million in Series B+ Financing to Advance Innovative Therapies to Drug-resistant...

    Details : InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and Chi...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    May 09, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    ImmVira Enters Clinical Development in Combination Therapy of MVR-T3011 IT and MEK inhibitor in the U.S.

    Details:

    MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells.


    Lead Product(s): T3011,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: PreclinicalProduct Type: Microorganism

    Sponsor: F. Hoffmann-La Roche

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement April 19, 2022

    blank

    04

    ImmVira

    China
    arrow
    World Dairy Expo
    Not Confirmed

    ImmVira

    China
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : T3011,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : F. Hoffmann-La Roche

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    ImmVira Enters Clinical Development in Combination Therapy of MVR-T3011 IT and MEK inhibitor in th...

    Details : MVR-T3011, ImmVira's proprietary 3-in-1oncolytic herpes simplex virus ("oHSV"), is a novel genetically engineered oHSV which aims to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells.

    Product Name : Undisclosed

    Product Type : Microorganism

    Upfront Cash : Undisclosed

    April 19, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Details:

    Alectinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.


    Lead Product(s): Alectinib Hydrochloride,Alpelisib,Anastrozole,Atezolizumab,Bevacizumab,Capecitabine,Carboplatin,Cobimetinib,

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Genentech | Oregon Health and Science University

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 14, 2022

    blank

    05

    OHSU Knight Cancer Institute

    Country
    arrow
    World Dairy Expo
    Not Confirmed

    OHSU Knight Cancer Institute

    Country
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Alectinib Hydrochloride,Alpelisib,Anastrozole,Atezolizumab,Bevacizumab,Capecitabine,Carboplatin,Cobimetinib,

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Genentech | Oregon Health and Science University

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    SMMART Adaptive Clinical Treatment (ACT) Trial

    Details : Alectinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    February 14, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

    Details:

    Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arteriovenous Malformations.


    Lead Product(s): Cobimetinib,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Genentech

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable November 18, 2021

    blank

    06

    University of Arkansas

    Country
    arrow
    World Dairy Expo
    Not Confirmed

    University of Arkansas

    Country
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cobimetinib,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Genentech

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

    Details : Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Arteriovenous Malformations.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    November 18, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

    Details:

    Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.


    Lead Product(s): Peg L asparaginase,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Enzyme

    Sponsor: Oregon Health and Science University | Genentech | Servier

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 05, 2021

    blank

    07

    OHSU Knight Cancer Institute

    Country
    arrow
    World Dairy Expo
    Not Confirmed

    OHSU Knight Cancer Institute

    Country
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Peg L asparaginase,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Oregon Health and Science University | Genentech | Servier

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancre...

    Details : Calaspargase Pegol is a Enzyme drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.

    Product Name : Undisclosed

    Product Type : Enzyme

    Upfront Cash : Inapplicable

    September 05, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma

    Details:

    Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.


    Lead Product(s): Cobimetinib,Vemurafenib,Atezolizumab

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IIProduct Type: Miscellaneous

    Sponsor: Clinical Research Technology

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 25, 2021

    blank

    08

    Fondazione Melanoma Onlus

    Country
    arrow
    World Dairy Expo
    Not Confirmed

    Fondazione Melanoma Onlus

    Country
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Cobimetinib,Vemurafenib,Atezolizumab

    Therapeutic Area : Oncology

    Highest Development Status : Phase II

    Partner/Sponsor/Collaborator : Clinical Research Technology

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Mel...

    Details : Cobimetinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Melanoma.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    January 25, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Revolution Medicines to Present Interim Data from Phase 1b/2 Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors

    Details:

    The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mutations.


    Lead Product(s): Vociprotafib,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 12, 2020

    blank

    09

    Revolution Medicines

    U.S.A
    arrow
    World Dairy Expo
    Not Confirmed

    Revolution Medicines

    U.S.A
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Vociprotafib,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Revolution Medicines to Present Interim Data from Phase 1b/2 Trial Combining RMC-4630 with Cobimet...

    Details : The ongoing Phase 1b/2 RMC-4630-02 trial is designed to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of RMC-4630 and cobimetinib in adult patients with relapsed/refractory solid tumors that harbor specific genomic mut...

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Inapplicable

    October 12, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing

    Details:

    Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.


    Lead Product(s): Ifebemtinib,Cobimetinib

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Miscellaneous

    Sponsor: Ennovation Ventures

    Deal Size: $19.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing September 03, 2020

    blank

    10

    InxMed

    China
    arrow
    World Dairy Expo
    Not Confirmed

    InxMed

    China
    arrow
    World Dairy Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ifebemtinib,Cobimetinib

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Ennovation Ventures

    Deal Size : $19.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing

    Details : Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.

    Product Name : Undisclosed

    Product Type : Miscellaneous

    Upfront Cash : Undisclosed

    September 03, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Topical

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    ABOUT THIS PAGE

    Looking for 934660-93-2 / Cobimetinib API manufacturers, exporters & distributors?

    Cobimetinib manufacturers, exporters & distributors 1

    68

    PharmaCompass offers a list of Cobimetinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cobimetinib manufacturer or Cobimetinib supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cobimetinib manufacturer or Cobimetinib supplier.

    PharmaCompass also assists you with knowing the Cobimetinib API Price utilized in the formulation of products. Cobimetinib API Price is not always fixed or binding as the Cobimetinib Price is obtained through a variety of data sources. The Cobimetinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Cobimetinib

    Synonyms

    934660-93-2, Gdc-0973, Xl518, Xl-518, Gdc 0973, Rg7420

    Cas Number

    934660-93-2

    Unique Ingredient Identifier (UNII)

    ER29L26N1X

    About Cobimetinib

    Cobimetinib is an orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineoplastic activity. Cobimetinib specifically binds to and inhibits the catalytic activity of MEK1, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation and activation and decreased tumor cell proliferation. Preclinical studies have demonstrated that this agent is effective in inhibiting the growth of tumor cells bearing a B-RAF mutation, which has been found to be associated with many tumor types. A threonine-tyrosine kinase and a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors, MEK1 is required for the transmission of growth-promoting signals from numerous receptor tyrosine kinases.

    Cobimetinib Fumarate Manufacturers

    A Cobimetinib Fumarate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cobimetinib Fumarate, including repackagers and relabelers. The FDA regulates Cobimetinib Fumarate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cobimetinib Fumarate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    Cobimetinib Fumarate Suppliers

    A Cobimetinib Fumarate supplier is an individual or a company that provides Cobimetinib Fumarate active pharmaceutical ingredient (API) or Cobimetinib Fumarate finished formulations upon request. The Cobimetinib Fumarate suppliers may include Cobimetinib Fumarate API manufacturers, exporters, distributors and traders.

    Cobimetinib Fumarate GMP

    Cobimetinib Fumarate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Cobimetinib Fumarate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cobimetinib Fumarate GMP manufacturer or Cobimetinib Fumarate GMP API supplier for your needs.

    Cobimetinib Fumarate CoA

    A Cobimetinib Fumarate CoA (Certificate of Analysis) is a formal document that attests to Cobimetinib Fumarate's compliance with Cobimetinib Fumarate specifications and serves as a tool for batch-level quality control.

    Cobimetinib Fumarate CoA mostly includes findings from lab analyses of a specific batch. For each Cobimetinib Fumarate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Cobimetinib Fumarate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cobimetinib Fumarate EP), Cobimetinib Fumarate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cobimetinib Fumarate USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search